Sorafenib is a protein kinase inhibitor, a drug approved for primary renal cell cancer,radioactive iodine resistant advanced thyroid carcinoma,unresectable hepatocellular carcinoma.It is an inhibitor of Raf kinase,VEGF receptor 2 and 3, platelet derived growth factor (PDGF) and c kit, the receptor of stem cell factor.Sorafenib undergo oxidative metabolism with a half life of 25-48hours and is metabolised by liver.Common adverse effects of sorafenib include dermatological events like rash, palmar-plantar erythrodysesthesia.Others include diarrhoea, fatigue,headache ,abdominal pain,nausea.Periodic blood tests to monitor complete blood counts as well as function of organs like kidney and liver are advised.Our aim is to present a patient of sixteen years of age, a known case retroperitoneal fibromatosis,post surgical resection on sorafenib with previous normal vision proceeded to diminution of vision in both eyes associated with fundus changes suggesting demyelinating optic neuropathy highlighting the importance of baseline ocular examination before starting a chemotherapeutic agent like sorafenib and periodic follow up for visual complaints after initiating the treatment .